Results 21 to 30 of about 4,805 (202)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen [PDF]

Current Oncology
Treatment for relapsed/refractory multiple myeloma (RRMM) is complex, with several classes of drugs that can be combined into doublet, triplet, or quadruplet regimens.
Andrew Whiteley, Stephen C. Ijioma, David Ray, Spencer S. Langerman, Ellen Hu, Amy Pierre, Tomer Mark, Habte Yimer   +7 more
doaj   +2 more sources

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. [PDF]

Am J Hematol
ABSTRACT Preclinical studies showed a synergistic antileukemia activity with combination of selective XPO1 inhibitor selinexor (SEL) and venetoclax (VEN), with potential to overcome VEN resistance by reducing the anti‐apoptotic protein MCL1. In an investigator‐sponsored, open‐label, phase Ib study (NCT03955783), adult patients with relapsed or ...
Ball S, Awan FT, Tomlinson BK, Stopczynski T, Fischer MA, Zhao Z, Fedorov K, Kishtagari A, Mohan SR, Ayers GD, Byrne MT, Savona MR.   +11 more
europepmc   +2 more sources

Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E

Frontiers in Oncology, 2021
Selinexor is an FDA approved selective inhibitor of the nuclear export protein exportin-1 (XPO1) and causes specific cancer cell death via nuclear accumulation of tumor suppressor proteins.
Jack G. Fisher, Christopher J. Walker, Amber DP. Doyle, Peter WM. Johnson, Francesco Forconi, Mark S. Cragg, Yosef Landesman, Salim. I. Khakoo, Matthew D. Blunt   +8 more
doaj   +1 more source

The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study. [PDF]

, 2022
Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens.
Bakhshi, Sameer, Caimi, Paolo, Canales, Miguel, Casasnovas, Rene-Olivier, Cavallo, Federica, Chamoun, Kamal, Choquet, Sylvain, Corona, Kelly, Cruz, Fatima De la, Egyed, Miklos, Follows, George, Gurion, Ronit, Hamad, Nada, Hill, Brian, Jaeger, Ulrich, Kalakonda, Nagesh, Ku, Matthew, Kuruvilla, John, Maerevoet, Marie, Offner, Fritz, Samal, Priyanka, Sancho, Juan-Manuel, Schuster, Michael, Shah, Jatin, Thieblemont, Catherine, Vassilakopoulos, Theodoros P, Vermaat, Joost SP, Warzocha, Krzysztof, Xu, Jenny, Zijlstra, Josée M   +29 more
core   +7 more sources

miR-34a-Mediated Survivin Inhibition Improves the Antitumor Activity of Selinexor in Triple-Negative Breast Cancer

Pharmaceuticals, 2021
Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Here, we pursued a combinatorial therapeutic approach to enhance the activity of selinexor, the first-in-class XPO1 inhibitor, by miR-34a ectopic expression ...
Silvia Martini, Valentina Zuco, Monica Tortoreto, Stefano Percio, Elisa Campi, Rihan El Bezawy, Valentina Doldi, Yosef Landesman, Marzia Pennati, Nadia Zaffaroni   +9 more
doaj   +1 more source

Selinexor—A Drug Review [PDF]

Indian Journal of Medical and Paediatric Oncology, 2021
AbstractSelinexor developed by Karyopharm Therapeutics is the first orally available small-molecule inhibitor of exportin-1 (XPO1). XPO-1 is a protein transporter responsible for the export of macromolecules such as tumor suppressor proteins and oncoprotein mRNAs from the nucleus to the cytoplasm; its inhibition results in blocking of multiple ...
Hridya Jayamohanan, Vaibhav Venniyoor, Keechilat Pavithran   +2 more
openaire   +1 more source

Combining selinexor with alisertib to target the p53 pathway in neuroblastoma

Neoplasia: An International Journal for Oncology Research, 2022
Neuroblastoma accounts for 15% of cancer-related deaths in children, highlighting an unmet need for novel therapies. Selinexor is a small molecule inhibitor of XPO1.
Rosa Nguyen, Hong Wang, Ming Sun, Dong Geun Lee, Junmin Peng, Carol J. Thiele   +5 more
doaj   +1 more source

Selinexor in Combination With Weekly Paclitaxel in Patients With Metastatic Solid Tumors: Results of an Open Label, Single-Center, Multi-Arm Phase 1b Study With Expansion Phase in Ovarian Cancer [PDF]

, 2023
OBJECTIVE: Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound which blocks Exportin-1 (XPO1). Our objective was to determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of selinexor and weekly ...
Akhmedzhanov, Fechukwu, Brink, Amanda L, Carter, Brett, Coleman, Robert L, Fu, Siqing, Gershenson, David, Gong, Jing, Hong, David S, Jazaeri, Amir, Leung, Cheuk Hong, Lin, Heather, McQuinn, Lacey, Meric-Bernstam, Funda, Naing, Aung, Pant, Shubham, Piha-Paul, Sarina, Shah, Jatin, Sood, Anil K, Tsimberidou, Apostolia, Westin, Shannon N, Yilmaz, Bulent   +20 more
core   +2 more sources

Overview of Ocular Side Effects of Selinexor [PDF]

The Oncologist, 2021
Abstract Background The aim of this review is to elucidate the type and frequency of ocular adverse events associated with selinexor with a goal to quantify the occurrence of these events in our investigator-initiated trial.
Nagham Al-Zubidi, Dan S. Gombos, David S. Hong, Vivek Subbiah, Siqing Fu, Jordi Rodon Ahnert, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Daniel D. Karp, Funda Meric Bernstam, Aung Naing   +10 more
openaire   +2 more sources

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma [PDF]

, 2022
[Objective] Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma.[Materials & methods] HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research
Abdul Razak, Albiruni R., Attia, Steven, Chawla, Sant P., Chmielowski, Bartosz, Gilligan, Adrienne M., Gounder, Mrinal, Grignani, Giovanni, Jones, Robin L., Kauffman, Michael, Leong, Hoyee, Ma, Xiwen, Martín-Broto, Javier, Riedel, Richard F., Schuetze, Scott M., Shacham, Sharon, Shah, Jatin, Somaiah, Neeta, Vincenzi, Bruno, Wagner, Andrew J.   +18 more
core   +1 more source